Magnetic Particle Imaging (MPI) is a new imaging modality directly detecting iron oxide nanoparticle tracers using time varying magnetic fields. Because the tracer is not normally found in the body, MPI images have exceptional contrast and high sensitivity. Usefully thought of "nuclear medicine" but with no radiation and with nanoparticles, the technique has imminent applications in cell tracking, blood pool imaging (e.g. perfusion), and angiography. Magnetic Insight (MI) has introduced magnetic particle imaging into the preclinical diagnostic research market enabling quantitative cell tracking, imaging of vascular function, detecting metastatic tumors, visualizing inflammation, CAR-T cell therapies and initial research into regenerative medicine. This capability supports the acceleration of preclinical research with direct translation into the clinic. Overcoming major deficiencies with current clinical and translational research imaging techniques. Magnetic Particle Imaging (MPI) -- an ultrasensitive, safe and quantitative technology, harnessing high contrast detection of iron oxide nanoparticles -- provides faster, safer and more accurate detection of cells, blood flow and targeted biological events. MPI is the first molecular imaging technique simultaneously capable of nanomolar sensitivity, absolute quantitation, resolution independent of depth, and with tracer detection from weeks to months: a functional imaging modality similar to PET, SPECT and optical where real time biological events can be monitored verses anatomical imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). MPI offers the ability to target biomarkers, introduced into the cell and as a vascular tracer to support real-time blood flow and vascular architecture all with direct quantitation. Harnessing the magnetic properties of iron oxide nanoparticles, visualization and quantitation is specific, direct and unobstructed by tissue depth at exquisite sensitivity and with elegant resolution.
